DIA Biosimilars 2013

Celerion

Parthenon Capital acquires Bracket

Friday, August 16, 2013 10:15 AM

Bracket, a specialty services provider, has been acquired by Parthenon Capital Partners, a growth-oriented private equity firm based in Boston and San Francisco, from Express Scripts Holding Company.

More... »

Cenduit: Now with Patient Reminders

Celerion becomes first U.S.-based CRO to receive full AAHRPP accreditation

Monday, September 17, 2012 03:39 PM

Celerion, a provider of innovative early stage drug development solutions based in Lincoln, Neb., has been awarded full accreditation by the Association for the Accreditation Human Research Protection Programs (AAHRPP), an independent, non-profit accrediting body. Celerion's clinical facilities in Lincoln, Neptune, N.J. and Phoenix, Ariz., have achieved the milestone.

More... »

CRF Health – eCOA Forum

Akesis names John L. Capicchioni as new president

Thursday, May 31, 2012 12:34 PM

Akesis, a Lake Wylie, S.C.-based contract research firm specializing in phase II-IV clinical dermatology services and regulatory affairs consulting, has appointed John L. Capicchioni as its new president.

More... »

Celerion and Ricerca Biosciences form The Biosimilars Alliance

Thursday, March 1, 2012 11:23 AM

Lincoln, Neb.-based Celerion, a provider of early-stage drug development solutions, and Ricerca Biosciences, which offer discovery, preclinical and development services, have formed “The Biosimilars Alliance,” focused on preclinical and early clinical assessment of biologics manufactured by a new supplier.

More... »

Celerion receives ANVISA certification

Friday, June 10, 2011 11:33 AM

Lincoln, Neb.-based Celerion, a provider of early-stage drug development solutions, has announced that its clinical research operations in Belfast, Northern Ireland, and its clinical research and bioanalytical services operations in Lincoln, Neb., have been certified by the Brazilian National Health Surveillance Agency (Agência Nacional de Vigilância Sanitária – ANVISA). 

More... »

Celerion awarded LEED green building certification

Friday, May 27, 2011 10:55 AM

Celerion, a provider of early stage drug development solutions, has been awarded LEED Silver established by the U.S. Green Building Council and verified by the Green Building Certification Institute (GBCI). LEED is the nation’s program for the design, construction and operation of high performance green buildings.

More... »

Celerion gains membership in U.K. respiratory cluster

Tuesday, March 29, 2011 12:11 PM

CRO Celerion, which provides early-stage drug development solutions, said its Belfast facility has gained membership within the U.K. Respiratory Therapeutic Capability Cluster. Celerion will work with key decision makers in the U.K. to develop and execute phase I and IIa studies with targeted patient populations.

More... »

MDS’ Early-Stage CRO Reborn as Celerion

Monday, March 29, 2010 01:30 PM

Part of MDS’ early-stage contract research organization (CRO), which was sold off in two parts earlier this month, is re-emerging as Celerion, a CRO owned by a group of private investors.

More... »

CenterWatch Drugs in Clinical Trials Database Library. Drug intelligence right at your fingertips.
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs